ReviewFrontiers in allergy2026
Artificial intelligence-assisted type 2 inflammatory endotyping in CRSwNP: from Sinus CT and digital pathology to biologic decision support.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous rhinologic disease frequently driven by type 2 inflammation, yet routine clinical phenotyping remains insufficient for endotype-informed management. Conventional markers, including blood eosinophils, serum immunoglobulin E (IgE), fractional exhaled nitric oxide, tissue eosinophilia, nasal polyp score, and sinus computed tomography (CT) scores, provide useful but incomplete information. Artificial intelligence (AI) enables integration of sinus CT, radiomic features, digital pathology, biomarkers, comorbidities, and follow-up treatment outcomes. Emerging studies suggest that CT-based AI supports non-invasive identification of eosinophilic or type 2-high disease, whereas digital pathology links routine histology with inflammatory and molecular endotypes. However, published evidence remains dominated by retrospective single-modality studies or partial multi-source integration, and no model has yet jointly integrated sinus CT, digital whole-slide pathology, and biomarkers in CRSwNP. Additional limitations include heterogeneous endotype labels, insufficient external validation, and uncertain clinical utility for biologic decision-making. This Mini Review synthesizes existing single-modality artificial intelligence pipelines, contextualizes CRSwNP as a representative disease model for AI-driven type 2 inflammatory endotyping, and proposes a clinically oriented, multimodal interpretable scoring framework integrating sinus imaging and digital pathology to support precision type 2 stratification in CRS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.